Copyright
©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jan 28, 2016; 22(4): 1727-1728
Published online Jan 28, 2016. doi: 10.3748/wjg.v22.i4.1727
Published online Jan 28, 2016. doi: 10.3748/wjg.v22.i4.1727
Treatment of chronic hepatitis B patients with tyrosine-methionine-aspartate-aspartate mutations
Aylin Calica Utku, Oguz Karabay, Department of Infectious Diseases and Clinical Microbiology, Sakarya University Training and Research Hospital, 54200 Sakarya, Turkey
Author contributions: Calica Utku A and Karabay O designed research, performed research; Calica Utku A wrote the paper.
Conflict-of-interest statement: There is no conflict of interest in this study.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Aylin Calica Utku, Department of Infectious Diseases and Clinical Microbiology, Sakarya University Training and Research Hospital, Street of Adnan Menderes, 54200 Sakarya, Turkey. aylindoctor@hotmail.com
Received: April 18, 2015
Peer-review started: April 21, 2015
First decision: June 19, 2015
Revised: July 2, 2015
Accepted: October 12, 2015
Article in press: October 13, 2015
Published online: January 28, 2016
Peer-review started: April 21, 2015
First decision: June 19, 2015
Revised: July 2, 2015
Accepted: October 12, 2015
Article in press: October 13, 2015
Published online: January 28, 2016
Core Tip
Core tip: Lamivudine is a nucleoside analogue that has been used in treatment of chronic hepatitis B. The only drawback of lamivudin is drug resistance during the treatment. Entecavir and tenofovir are potent hepatitis B virus inhibitors with a high barrier to resistance . They can used as first-line monotherapies. The main problem of lamivudine treatment is development of mutation in the tyrosine-methionine-aspartate-aspartate (YMDD) motif. Treatment with lamivudine may cause exacerbation of hepatitis in patients with YMDD mutation. These patients should use YMDD mutant form-effective drugs.